Pancreatic Cancer Research

ResearcherUniversity of Maryland Medical CenterActive in the last 2 years

Michele Reni

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6463-0293; OpenAlex author ID A5003425445, A5063476006, A5137977122, A5159692107. Sources: ClinicalTrials.gov.

Their work

Papers
137 (first author 7, last author 23)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
295
Papers, trials and grants by year

2011: 5 papers · 2012: 4 papers · 2013: 7 papers · 2014: 4 papers · 2015: 2 papers · 2016: 10 papers · 2017: 7 papers · 2018: 9 papers · 2019: 8 papers · 2020: 12 papers, 1 trial · 2021: 12 papers · 2022: 11 papers · 2023: 15 papers · 2024: 10 papers · 2025: 8 papers · 2026: 13 papers

Papers 50 of 137

  1. Paired Duodenal and Salivary Microbiome Analysis in Pancreatic Cancer Without Duct Obstruction. Co-author DOI 10.1002/ueg2.70179↗
  2. Designing a national network of pancreas units: the Italian model for high-quality pancreatic cancer care. Co-author DOI 10.1007/s13304-026-02598-7↗
  3. Impact of nutritional status on chemotherapy delivery and outcomes in advanced pancreatic cancer: A prospective multicenter study. Co-author DOI 10.1016/j.clnu.2025.106573↗
  4. Pancreatic adenocarcinoma nutritional-clinical index (PANCIN): A novel prognostic tool in advanced pancreatic cancer. Co-author DOI 10.1016/j.dld.2026.02.015↗
  5. Toward precision chemotherapy in pancreatic ductal adenocarcinoma: molecular, transcriptomic and clinical determinants. Last author DOI 10.1016/j.dld.2026.02.020↗
  6. A robust biomarker combining radiomic and CA19.9 information to predict distant relapse-free survival after radiochemotherapy in pancreatic cancer. Co-author DOI 10.1016/j.dld.2026.09.026↗
  7. Short-term versus long-course neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results f… Co-author DOI 10.1016/j.eclinm.2026.104190↗
  8. Impact of center-level protocol adherence on neoadjuvant treatment outcome in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.ejca.2026.117033↗
  9. Daraxonrasib in refractory PDAC: A one-eyed king in the land of the blind? First author DOI 10.1016/j.medj.2026.101227↗
  10. Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the … Co-author DOI 10.1016/s0140-6736(25)01685-x↗
  11. Actual Five-year Survival After Neoadjuvant Therapy and Resection for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000007214↗
  12. Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Co-author DOI 10.1245/s10434-026-19218-8↗
  13. ASO Visual Abstract: Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Co-author DOI 10.1245/s10434-026-19370-1↗
  14. Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants. Last author DOI 10.1002/cam4.70364↗
  15. Exploring external validity of chemotherapy for pancreatic ductal adenocarcinoma in real life. Co-author DOI 10.1016/j.dld.2024.06.025↗
  16. Diagnostic delay at diagnosis and time-to-treatment influence overall survival of pancreatic cancer patients. Co-author DOI 10.1016/j.dld.2025.03.009↗
  17. Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Application in Real world: multi-Institutional … Co-author DOI 10.1016/j.esmoop.2024.104001↗
  18. Gastrointestinal symptoms in the journey of pancreatic cancer patients. Co-author DOI 10.1080/14737140.2025.2517888↗
  19. Anatomically resectable versus biologically borderline resectable pancreatic cancer definition: refining the border beyond anatomical criteria and biological a… Co-author DOI 10.1093/bjsopen/zraf033↗
  20. Prognostic Validation of Perineural Invasion Severity Score in Pancreatic Cancer: A Prospective Study. Co-author DOI 10.1097/sla.0000000000006920↗
  21. Temporal Validation of an FDG-PET-Radiomic Model for Distant-Relapse-Free-Survival After Radio-Chemotherapy for Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers17061036↗
  22. Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma. First author DOI 10.1016/j.ctro.2024.100778↗
  23. Exploring the optimal therapeutic management of stage ypIA pancreatic ductal adenocarcinoma patients in the era of primary chemotherapy. Last author DOI 10.1016/j.dld.2023.07.006↗
  24. Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.dld.2023.07.033↗
  25. Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients. Last author DOI 10.1016/j.ejca.2024.114226↗
  26. Communication, understanding and engagement of patients with pancreatic cancer at time of diagnosis. Co-author DOI 10.1016/j.pan.2024.02.008↗
  27. A pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma patients bearing germline BRCA or other DNA damage repair system variants. Last author DOI 10.1016/j.pan.2024.09.006↗
  28. Pathologic complete response following neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma: Impact on survival and recurrence. Co-author DOI 10.1016/j.surg.2024.07.026↗
  29. Isolated lung metastases from pancreatic ductal adenocarcinoma (PDAC): Diagnostic and therapeutic challenges of a different disease. Last author DOI 10.1053/j.seminoncol.2024.04.001↗
  30. Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarci… Co-author DOI 10.1186/s12885-024-12936-w↗
  31. Very Early Recurrence After Curative Resection for Pancreatic Ductal Adenocarcinoma: Proof of Concept for a "Biological R2 Definition". Co-author DOI 10.1245/s10434-024-15105-2↗
  32. Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer. Co-author DOI 10.1001/jamaoncol.2022.7358↗
  33. Ex-vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy. Co-author DOI 10.1002/deo2.152↗
  34. Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA… Last author DOI 10.1007/s00280-023-04585-w↗
  35. The Role of Neoadjuvant FOLFIRINOX in Borderline Resectable Pancreatic Cancer: A Network Meta-Analysis. Last author DOI 10.1007/s12029-023-00923-6↗
  36. Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Samples. Co-author DOI 10.1016/j.cgh.2022.10.014↗
  37. The role of biliary events in treatment and survival of patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.dld.2023.04.015↗
  38. Pro-tumor Tfh2 cells induce detrimental IgG4 production and PGE2-dependent IgE inhibition in pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2023.104819↗
  39. Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adapti… Co-author DOI 10.1016/j.eclinm.2023.101897↗
  40. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary a… Co-author DOI 10.1016/j.esmoop.2022.100777↗
  41. Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.01.016↗
  42. Lessons and open questions in borderline resectable pancreatic cancer. Co-author DOI 10.1016/s2468-1253(22)00393-4↗
  43. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv). Last author DOI 10.1038/s41416-022-02086-w↗
  44. Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world stud… Co-author DOI 10.1186/s12885-023-11377-1↗
  45. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  46. Immunomodulatory Effects of Endoscopic Ultrasound-Guided Thermal Ablation in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15143704↗
  47. Is the Delphi's Oracle Pertinent to Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma? Co-author DOI 10.1001/jamaoncol.2022.4673↗
  48. Evolving pancreatic cancer treatment: From diagnosis to healthcare management. Last author DOI 10.1016/j.critrevonc.2021.103571↗
  49. Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients. Last author DOI 10.1016/j.ctrv.2022.102357↗
  50. Pancreatic cancer: still a cold case? Co-author DOI 10.1016/s1470-2045(22)00394-1↗

Trials 1

  1. PAXG Out in the Country Principal investigator NCT04480268↗

Closest collaborators

The 25 strongest of 295 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Massimo Falconi · 66 shared papers, 2011–2026 · strength 8.42
  2. Giulia Orsi · 34 shared papers, 2020–2026 · strength 6.71
  3. Marina Macchini · 38 shared papers, 2018–2026 · strength 6.31
  4. Gabriele Capurso · 22 shared papers, 2019–2026 · strength 3.80
  5. Paolo Giorgio Arcidiacono · 26 shared papers, 2012–2026 · strength 3.61
  6. Stefano Crippa · 23 shared papers, 2016–2026 · strength 3.43
  7. Domenico Tamburrino · 18 shared papers, 2018–2026 · strength 3.05
  8. Giulio Belfiori · 17 shared papers, 2017–2026 · strength 2.88
  9. Stefano Partelli · 19 shared papers, 2015–2026 · strength 2.68
  10. Gianpaolo Balzano · 29 shared papers, 2012–2026 · strength 2.61
  11. Umberto Peretti · 19 shared papers, 2017–2025 · strength 2.53
  12. Stefano Cascinu · 20 shared papers, 2015–2025 · strength 2.43
  13. Marco Schiavo Lena · 12 shared papers, 2022–2026 · strength 2.25
  14. Nicolò Pecorelli · 12 shared papers, 2019–2026 · strength 2.25
  15. Michèle Milella · 18 shared papers, 2011–2026 · strength 2.19
  16. Claudio Doglioni · 24 shared papers, 2011–2025 · strength 2.14
  17. Diego Palumbo · 11 shared papers, 2021–2026 · strength 2.11
  18. Francesco DE COBELLI · 11 shared papers, 2020–2026 · strength 1.73
  19. Catia Carconi · 8 shared papers, 2024–2026 · strength 1.64
  20. Lívia Archibugi · 10 shared papers, 2019–2026 · strength 1.60
  21. Giampaolo Tortora · 13 shared papers, 2018–2026 · strength 1.59
  22. Letizia Procaccio · 8 shared papers, 2023–2026 · strength 1.46
  23. Ilario Giovanni Rapposelli · 9 shared papers, 2021–2026 · strength 1.45
  24. Maria Chiara Petrone · 11 shared papers, 2012–2026 · strength 1.42
  25. Giulia Gasparini · 7 shared papers, 2023–2026 · strength 1.42

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.